A potential therapeutic combination for treatment of COVID-19: Synergistic effect of DPP4 and RAAS suppression
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Phyu Phyu Khin | - |
dc.contributor.author | Cha, Seon-Heui | - |
dc.contributor.author | Jun, Hee-Sook | - |
dc.contributor.author | Lee, Jong Han | - |
dc.date.available | 2021-01-14T00:40:30Z | - |
dc.date.created | 2020-08-27 | - |
dc.date.issued | 2020-11 | - |
dc.identifier.issn | 0306-9877 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/79739 | - |
dc.description.abstract | COVID-19, caused by the novel coronavirus SARS-CoV-2, is an abbreviated name for coronavirus disease 2019. COVID-19 became a global pandemic in early 2020. It predominantly affects not only the upper and lower respiratory tract, but also multiple organs, including the kidney, heart, and brain. The mortality of COVID-19 patients is high in men and in elderly patients with age-related diseases such as hypertension and diabetes. The angiotensin converting enzyme-2 (ACE-2), a component in the renin–angiotensin–aldosterone system (RAAS), plays as cell surface receptors for SARS-CoV-2. A recent study proved that coronavirus SARS-CoV-2 also uses dipeptidyl peptidase-4 (DPP4, also known as adenosine deaminase complexing protein 2, CD26) as a co-receptor when entering cells. In addition, DPP4 is also implicated in the regulation of the immune response. Thus, the combination of DPP4 inhibition and suppression of ACE-2/RAAS may be a novel therapeutic strategy for combating this pandemic. © 2020 | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Churchill Livingstone | - |
dc.relation.isPartOf | Medical Hypotheses | - |
dc.title | A potential therapeutic combination for treatment of COVID-19: Synergistic effect of DPP4 and RAAS suppression | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000598953600002 | - |
dc.identifier.doi | 10.1016/j.mehy.2020.110186 | - |
dc.identifier.bibliographicCitation | Medical Hypotheses, v.144 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85089546916 | - |
dc.citation.title | Medical Hypotheses | - |
dc.citation.volume | 144 | - |
dc.contributor.affiliatedAuthor | Phyu Phyu Khin | - |
dc.contributor.affiliatedAuthor | Jun, Hee-Sook | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Angiotensin converting enzyme-2 | - |
dc.subject.keywordAuthor | Coronavirus SARS-CoV-2 | - |
dc.subject.keywordAuthor | Dipeptidyl peptidase-4 | - |
dc.subject.keywordAuthor | Renin–angiotensin–aldosterone system | - |
dc.subject.keywordPlus | angiotensin converting enzyme 2 | - |
dc.subject.keywordPlus | dipeptidyl peptidase IV | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | coronavirus disease 2019 | - |
dc.subject.keywordPlus | cytokine storm | - |
dc.subject.keywordPlus | disease course | - |
dc.subject.keywordPlus | enzyme activity | - |
dc.subject.keywordPlus | enzyme inhibition | - |
dc.subject.keywordPlus | enzyme repression | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | immunoregulation | - |
dc.subject.keywordPlus | nonhuman | - |
dc.subject.keywordPlus | pandemic | - |
dc.subject.keywordPlus | renin angiotensin aldosterone system | - |
dc.subject.keywordPlus | Severe acute respiratory syndrome coronavirus 2 | - |
dc.subject.keywordPlus | T lymphocyte | - |
dc.subject.keywordPlus | virus cell interaction | - |
dc.subject.keywordPlus | virus entry | - |
dc.subject.keywordPlus | virus replication | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.